Cell line name |
SKBR3/TDR |
Accession |
CVCL_B3MN |
Resource Identification Initiative |
To cite this cell line use: SKBR3/TDR (RRID:CVCL_B3MN) |
Comments |
Population: Caucasian. Selected for resistance to: DrugBank; DB05773; Trastuzumab emtansine (T-DM1). Derived from site: Metastatic; Pleural effusion; UBERON=UBERON_0000175. |
Sequence variations |
- Gene deletion; HGNC; 1748; CDH1; Zygosity=Homozygous (from parent cell line).
- Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Homozygous (from parent cell line).
|
Disease |
Breast adenocarcinoma (NCIt: C5214) |
Species of origin |
Homo sapiens (Human)
(NCBI Taxonomy: 9606) |
Hierarchy |
Parent: CVCL_0033 (SK-BR-3) |
Sex of cell |
Female |
Age at sampling |
43Y |
Category |
Cancer cell line |
Publications | CLPUB00650 Sabbaghi Mehrjardi M.A. Uncovering mechanisms of acquired resistance to trastuzumab-emtansine (T-DM1) in HER2 positive breast cancer. Thesis PhD (2017), Universitat de Barcelona, Spain PubMed=28821558; DOI=10.1158/1078-0432.CCR-17-0696 Sabbaghi Mehrjardi M.A., Gil-Gomez G., Guardia C., Servitja S., Arpi O., Garcia-Alonso S., Menendez S., Arumi-Uria M., Serrano L., Salido M., Muntasell A., Martinez-Garcia M., Zazo S., Chamizo C., Gonzalez-Alonso P., Madoz-Gurpide J., Eroles P., Arribas J., Tusquets I., Lluch A., Pandiella A., Rojo F., Rovira A., Albanell J. Defective cyclin B1 induction in trastuzumab-emtansine (T-DM1) acquired resistance in HER2-positive breast cancer. Clin. Cancer Res. 23:7006-7019(2017) |
Cross-references |
Cell line databases/resources |
cancercelllines; CVCL_B3MN
|
Encyclopedic resources |
Wikidata; Q110433236
|
Entry history |
Entry creation | 16-Dec-2021 |
Last entry update | 05-Oct-2023 |
Version number | 5 |
---|